Daniel George, Md

This study tested a combination of two oral drugs, apalutamide and abiraterone acetate, plus prednisone in men with advanced prostate cancer that had stopped responding to standard hormone therapy. It specifically enrolled 50 African American and 50 Caucasian men to see how well …